These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1273915)

  • 1. Are dead cells responsible for allogeneic growth of organ cultures and cell suspensions of BALB/c Leydig cell tumors?
    Jacobs BB
    Transplantation; 1976 May; 21(5):433-6. PubMed ID: 1273915
    [No Abstract]   [Full Text] [Related]  

  • 2. Growth of tumors in allogeneic hosts after organ culture explantation. II. Tumor-host interactions.
    Jacobs BB
    J Natl Cancer Inst; 1969 Apr; 42(4):537-43. PubMed ID: 4887236
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of feeding syngeneic and allogeneic tissues on growth of an allotransplantable tumor.
    Breyere EJ; Heath JR
    Transplant Proc; 1977 Jun; 9(2):1459-63. PubMed ID: 878012
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space.
    Wenkel H; Chen PW; Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3202-8. PubMed ID: 10586943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of tumors as a result of graft-versus-host reaction.
    Cornelius EA
    Exp Hematol; 1973; 1(3):135-49. PubMed ID: 4153858
    [No Abstract]   [Full Text] [Related]  

  • 6. Apparent lack of immunogenicity of estrogen-induced testicular Leydig cell tumors in BALB/c mice.
    Huseby RA; Page RH
    Cancer Res; 1982 Nov; 42(11):4332-8. PubMed ID: 6751521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
    Ohashi M; Kobayashi A; Hara H; Miura Y; Yoshida K; Kushida M; Ikarashi Y; Mandai M; Kitajima M; Yoshida T; Aoki K
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2208-15. PubMed ID: 16609036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of donor immunocompetent cells in allograft rejection.
    Jacobs BB; Leonard L; Parks RC
    J Natl Cancer Inst; 1976 Aug; 57(2):345-8. PubMed ID: 1003516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone dependency of murine endocrine tumors in vivo and in organ culture: a correlative study.
    Jacobs BB; Huseby RA
    J Natl Cancer Inst; 1972 Oct; 49(4):1205-12. PubMed ID: 4343476
    [No Abstract]   [Full Text] [Related]  

  • 10. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Source of tumor cells influences their immune recognition by H-2-matched mice.
    Forni G; Varesio L; Giovarelli M; Landolfo S
    Transplantation; 1979 Jun; 27(6):433-5. PubMed ID: 462530
    [No Abstract]   [Full Text] [Related]  

  • 12. A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.
    Giovarelli M; Musiani P; Garotta G; Ebner R; Di Carlo E; Kim Y; Cappello P; Rigamonti L; Bernabei P; Novelli F; Modesti A; Coletti A; Ferrie AK; Lollini PL; Ruben S; Salcedo T; Forni G
    J Immunol; 1999 Nov; 163(9):4886-93. PubMed ID: 10528190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant cell arrest in thymus and spleen of mice bearing transplanted tumors.
    Haran-Ghera N; Krauthgamer R; Peled A
    J Immunol; 1981 Apr; 126(4):1241-4. PubMed ID: 6782158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity.
    Gordon LB; Nolan SC; Cserr HF; Knopf PM; Harling-Berg CJ
    J Immunol; 1997 Sep; 159(5):2399-408. PubMed ID: 9278331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen.
    Clark DA; Gorczynski RM; Blajchman MA
    Transfusion; 2008 May; 48(5):814-21. PubMed ID: 18298594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of anterior chamber-associated immune deviation (ACAID) by allogeneic intraocular tumors does not require splenic metastases.
    Niederkorn JY; Streilein JW
    J Immunol; 1982 Jun; 128(6):2470-4. PubMed ID: 6804562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective transformation of host lymphocytes in vivo by retrovirus-producing macrophages.
    Bosco MC; Musso T; Gusella GL; Giovarelli M; Forni M; Soleti A; Masuelli L; Modesti A; Forni G; Varesio L
    J Immunol; 1993 Jan; 150(1):278-89. PubMed ID: 8417128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological study of allogeneic tumor growth in mice bearing a glass cylinder.
    Filippa DA; Dosne Pasqualini C
    Medicina (B Aires); 1975; 35(1):29-36. PubMed ID: 1092950
    [No Abstract]   [Full Text] [Related]  

  • 19. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
    Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA
    Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of young nude mice for selection of subpopulations of cells with increased metastatic potential from nonsyngeneic neoplasms.
    Pollack VA; Fidler IJ
    J Natl Cancer Inst; 1982 Jul; 69(1):137-41. PubMed ID: 6954306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.